
1. travel med infect dis. 2014 jan-feb;12(1):40-7. doi: 10.1016/j.tmaid.2013.07.007.
epub 2013 aug 28.

use anti-malarial drugs risk developing eye disorders.

schneider c(1), adamcova m(2), jick ss(3), schlagenhauf p(4), miller mk(5), rhein
hg(6), meier cr(7).

author information: 
(1)basel pharmacoepidemiology unit, division clinical pharmacy and
epidemiology, department pharmaceutical sciences, university basel, basel,
switzerland. electronic address: schneiderc@uhbs.ch.
(2)safety risk management, f. hoffmann-la roche ltd., basel, switzerland.
electronic address: miriam.adamcova@roche.com.
(3)boston collaborative drug surveillance program, boston university school of
medicine, lexington, ma, usa. electronic address: sjick@bu.edu.
(4)university zuerich centre travel medicine, institute social and
preventive medicine, zuerich, switzerland. electronic address: pat@ifspm.uzh.ch.
(5)department epidemiology, genentech inc., south san francisco, usa.
electronic address: miller.katie@gene.com.
(6)safety risk management, f. hoffmann-la roche ltd., basel, switzerland.
electronic address: hans-georg.rhein@roche.com.
(7)basel pharmacoepidemiology unit, division clinical pharmacy and
epidemiology, department pharmaceutical sciences, university basel, basel,
switzerland; boston collaborative drug surveillance program, boston university
school medicine, lexington, ma, usa; hospital pharmacy, university hospital
basel, basel, switzerland. electronic address: meierch@uhbs.ch.

comment in
    travel med infect dis. 2014 jan-feb;12(1):1-2.

background: ocular toxicity described late 1950s some
anti-malarial drugs, limited information available comparison 
of ocular toxicity different anti-malarials.
methods: conducted follow-up study nested case-control analysis using
the general practice research database compare risk developing a
first-time diagnosis eye disorder exposure mefloquine,
chloroquine and/or proguanil atovaquone/proguanil use non-users. we
calculated incidence rates 95% confidence intervals (ci) odds ratios
using multivariate conditional logistic regression analyses.
results: included 83,148 patients identified 652 cases incident
eye disorder. incidence rates 95% ci eye disorders combined in
users mefloquine, chloroquine and/or proguanil, atovaquone/proguanil or
travellers using anti-malarials 5.3 (4.3-6.5), 7.1 (5.0-9.9), 6.3
(5.6-7.2) 5.1 (4.6-5.7), per 1000 person-years, respectively. compared 
non-users anti-malarials, adjusted odds ratio 95% ci nested
case-control analysis users mefloquine, chloroquine and/or proguanil, or
atovaquone/proguanil 1.33 (1.01-1.75), 1.61 (1.06-2.45), 1.25
(1.03-1.52), respectively.
conclusions: study provides evidence increased risk eye 
disorders users anti-malarials compared non-users anti-malarials.

copyright Â© 2013 elsevier ltd. rights reserved.

doi: 10.1016/j.tmaid.2013.07.007 
pmid: 24035311  [indexed medline]

